Founded in 1990 in Switzerland, Stragen is a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen is active in niche markets with more than 100* formulations developed and a portfolio of 40* products commercialized in several areas namely cardiology, anti-infectives and women’s health. The company has a global presence in over 60* countries with a direct footprint in key markets, predominantly France, Germany, Nordics, USA and Canada, and a growing presence in emerging markets such as Algeria, Vietnam and others.

*As of May 2023